Journal for ImmunoTherapy of Cancer: 11 (3)

Basic tumor immunology

Original research: ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers (31 March, 2023)
Zheng-Zheng Yu, Yun-Ya Liu, Wei Zhu, Ding Xiao, Wei Huang, Shan-Shan Lu, Hong Yi, Ting Zeng, Xue-Ping Feng, Li Yuan, Jie-Ya Qiu, Di Wu, Qi Wen, Jian-Hua Zhou, Wei Zhuang, Zhi-Qiang Xiao
Original research: Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment (29 March, 2023)
Christine McInnis, Shilpa Bhatia, Brinda Vijaykumar, Qiaomu Tian, Yanbo Sun, Del Leistritz-Edwards, Charles T Quinn, Ravi Uppaluri, Ann Marie Egloff, Lakshmi Srinivasan, Daniel C Pregibon, Anthony J Coyle, Glenn J Hanna
Original research: Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy (22 March, 2023)
Rasmus Erik Johansson Mortensen, Morten Orebo Holmström, Thomas Landkildehus Lisle, Jane P Hasselby, Gro L Willemoe, Özcan Met, Inge Marie Svane, Julia Johansen, Dorte L Nielsen, Inna M Chen, Mads Hald Andersen
Original research: Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation (16 March, 2023)
Yu Sun, Haoran Hu, Zheng Liu, Jian Xu, Yiyun Gao, Xinyu Zhan, Shun Zhou, Weizhe Zhong, Dongming Wu, Ping Wang, Zhuqing Rao, Lianbao Kong, Haoming Zhou
Original research: Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival (16 March, 2023)
Luigi D'Antonio, Cristiano Fieni, Stefania Livia Ciummo, Simone Vespa, Lavinia Lotti, Carlo Sorrentino, Emma Di Carlo
Original research: Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy (13 March, 2023)
Marit J van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J C van Stigt Thans, Thorbald Van Hall, Sjoerd H van der Burg
Original research: Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma (7 March, 2023)
Julie A Tomolonis, Xin Xu, Kshiti H Dholakia, Chunchao Zhang, Linjie Guo, Amy N Courtney, Siyue Wang, Julien Balzeau, Gabriel A Barragán, Gengwen Tian, Erica J Di Pierro, Leonid S Metelitsa
Original research: An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer (6 March, 2023)
Nicole L Wittwer, Alexander H Staudacher, Vasilios Liapis, Pina Cardarelli, Harriet Warren, Michael P Brown
Original research: Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma (3 March, 2023)
Alex Frias, Luca Di Leo, Asier Antoranz, Loulieta Nazerai, Marco Carretta, Valérie Bodemeyer, Chiara Pagliuca, Christina Dahl, Giuseppina Claps, Giulio Eugenio Mandelli, Madhavi Dipak Andhari, Maria Pires Pacheco, Thomas Sauter, Caroline Robert, Per Guldberg, Daniel Hargbøl Madsen, Francesco Cecconi, Francesca Maria Bosisio, Daniela De Zio
Original research:
Implication of ^99mTc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells
(1 March, 2023)
Yu Gao, Qi Luo, Zhichen Sun, Hannan Gao, Yue Yu, Yining Sun, Xiaotu Ma, Chuanhui Han, Jiyun Shi, Fan Wang
Original research: TFAM deficiency in dendritic cells leads to mitochondrial dysfunction and enhanced antitumor immunity through cGAS-STING pathway (1 March, 2023)
Tianqi Lu, Ziqi Zhang, Zhenfei Bi, Tianxia Lan, Hao Zeng, Yu Liu, Fei Mo, Jingyun Yang, Siyuan Chen, Xuemei He, Weiqi Hong, Zhe Zhang, Ruyu Pi, Wenyan Ren, Xiaohe Tian, Yuquan Wei, Min Luo, Xiawei Wei

Clinical/translational cancer immunotherapy

Original research: Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody (29 March, 2023)
Jeong A Park, Madelyn Espinosa-Cotton, Hong-fen Guo, Sebastien Monette, Nai-Kong V Cheung
Original research: Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor) (22 March, 2023)
Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S Yadav, Ai-Di Gu, Alexsandra B Espejo, Michelle Kinder, Curtis A Pettaway, John F Ward, Rebecca S S Tidwell, Patricia Troncoso, Paul G Corn, Christopher J Logothetis, Roland Knoblauch, Natalie Hutnick, Marco Gottardis, Charles G Drake, Padmanee Sharma, Sumit K Subudhi
Original research: First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC) (22 March, 2023)
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer, Ravi A Madan, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Ray Li, Kam Chan, Helen Cho, Megan Kaneda, I-Ming Wang, Jenny Zheng, Szu-Yu Tang, Robert Hollingsworth, Kenneth A Kern, Daniel P Petrylak
Original research: Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) (22 March, 2023)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David Braun, David Einstein, Paul J Catalano, Hans Hammers
Original research: BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer (20 March, 2023)
Chi Yin, Min Wang, Yingzhao Wang, Qijun Lin, Kaiyuan Lin, Hong Du, Chuandong Lang, Yuhu Dai, Xinsheng Peng
Original research: First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) (16 March, 2023)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurelien Marabelle, Jeffrey S Weber, John V Heymach
Original research: Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity (8 March, 2023)
Ming Zheng
Original research: Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy (8 March, 2023)
Prachi Bhave, Angela Hong, Serigne N Lo, Rebecca Johnson, Johanna Mangana, Douglas B Johnson, Ozgecan Dulgar, Zeynep Eroglu, Hui-Ling Yeoh, Andrew Haydon, Georg C Lodde, Elisabeth Livingstone, Adnan Khattak, Katharina Kähler, Axel Hausschild, Grant A McArthur, Alexander Maxwell Menzies, Georgina Long, Wei Wang, Matteo S Carlino
Original research: Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression (8 March, 2023)
Sofia Bruni, Florencia L Mauro, Cecilia J Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci

Commentary

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma (10 March, 2023)
Brian I Rini, James Brugarolas, Michael B Atkins

Immunotherapy biomarkers

Original research: Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI (14 March, 2023)
Emily Hoffmann, Mirjam Gerwing, Stephan Niland, Rolf Niehoff, Max Masthoff, Christiane Geyer, Lydia Wachsmuth, Enrica Wilken, Carsten Höltke, Walter L Heindel, Verena Hoerr, Regina Schinner, Philipp Berger, Thomas Vogl, Johannes A Eble, Bastian Maus, Anne Helfen, Moritz Wildgruber, Cornelius Faber
Original research: LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer (13 March, 2023)
Ting Zhao, Sheng Liu, Nasser H Hanna, Shadia Jalal, Xinchun Ding, Jun Wan, Cong Yan, Hong Du
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors (10 March, 2023)
Jasmine I Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, Eric Meffre, Lucia Jilaveanu, Dominika A Michalek, Stephen S Rich, Yariv Aizenbud, Adebowale Adeniran, Kevan C Herold, Matthew R Austin, Harriet Kluger
Accumulation of T-cell-suppressive PD-L1^high extracellular vesicles is associated with GvHD and might impact GvL efficacy
(10 March, 2023)
Rebecca Baur, Franziska Karl, Romy Böttcher-Loschinski, Andrej Stoll, Simon Völkl, Andreas Gießl, Cindy Flamann, Heiko Bruns, Ursula Schlötzer-Schrehardt, Martin Böttcher, Denis M Schewe, Thomas Fischer, Regina Jitschin, Andreas Mackensen, Dimitrios Mougiakakos
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab (7 March, 2023)
Eric D Routh, Mark G Woodcock, Wolfgang Beckabir, Steven P Vensko, Jonathan S Serody, Benjamin G Vincent
Original research: Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma (3 March, 2023)
Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou

Immune cell therapies and immune cell engineering

Serpin B9 controls tumor cell killing by CAR T cells (17 March, 2023)
Thomas Kimman, Anne Slomp, Anne Martens, Sarah Grabherr, Shuang Li, Eline van Diest, Jan Meeldijk, Jurgen Kuball, Monique C Minnema, Eric Eldering, Niels Bovenschen, Zsolt Sebestyén, Victor Peperzak
Original research: All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma (14 March, 2023)
Ziyi Peng, Jingya Wang, Jing Guo, Xin Li, Sheng Wang, Ying Xie, Hongmei Jiang, Yixuan Wang, Mengqi Wang, Meilin Hu, Qian Li, Yafei Wang, Jian-Qing Mi, Zhiqiang Liu
Original research: Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering (14 March, 2023)
Kathryn R Michels, Alyssa Sheih, Susana A Hernandez, Alissa H Brandes, Don Parrilla, Blythe Irwin, Anai M Perez, Hung-An Ting, Christopher J Nicolai, Timothy Gervascio, Seungjin Shin, Mark D Pankau, Mason Muhonen, Jessica Freeman, Sarah Gould, Rich Getto, Ryan P Larson, Byoung Y Ryu, Andrew M Scharenberg, Alessandra M Sullivan, Shon Green
Original research: CD47 expression is critical for CAR T-cell survival in vivo (14 March, 2023)
Alex N Beckett, Peter Chockley, Shondra M Pruett-Miller, Phuong Nguyen, Peter Vogel, Heather Sheppard, Giedre Krenciute, Stephen Gottschalk, Christopher DeRenzo
Original research: Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors (13 March, 2023)
Konstantinos Lontos, Yiyang Wang, Supriya K Joshi, Andrew T Frisch, McLane J Watson, Alok Kumar, Ashley V Menk, Yupeng Wang, Rachel Cumberland, Jason Lohmueller, Esteban Carrizosa, Benjamin Boyerinas, Greg M Delgoffe
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice (10 March, 2023)
Xinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K Jain

Letter

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
(21 March, 2023)
Zinal S Chheda, Sabine Mueller, Bindu Hegde, Akane Yamamichi, Lisa H Butterfield, Hideho Okada
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
(14 March, 2023)
Lena Immisch, George Papafotiou, Oliver Popp, Philipp Mertins, Thomas Blankenstein, Gerald Willimsky
Response to 'Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC' by Yang et al
(7 March, 2023)
Kun Li, Yunfei Qin, Linsen Ye

Oncolytic and local immunotherapy

Original research: Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1 (23 March, 2023)
Huy-Dung Hoang, Aida Said, Nasana Vaidya, Victoria H Gilchrist, Kyle Malone, Usha Kabilan, Serena Topshee, Xiao Xiang, An-Dao Yang, David Olagnier, Karen Mossman, Shawn T Beug, Seyed Mehdi Jafarnejad, Samuel T Workenhe, Tyson E Graber, Tommy Alain

Position article and guidelines

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology (31 March, 2023)
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey Weber, Laura C Cappelli
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies (14 March, 2023)
Michael B Atkins, Paolo A Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet Kluger, Ryan J Sullivan, Hussein Tawbi
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors (14 March, 2023)
Harriet Kluger, J Carl Barrett, Justin F Gainor, Omid Hamid, Michael Hurwitz, Theresa LaVallee, Rebecca A Moss, Roberta Zappasodi, Ryan J Sullivan, Hussein Tawbi, Elad Sharon
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy (14 March, 2023)
Naiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Sarah B Goldberg, Matthew D Hellmann, Ranee Mehra, Ina Rhee, Jong Chul Park, Harriet Kluger, Hussein Tawbi, Ryan J Sullivan

Review

Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature (6 March, 2023)
Lisa L Liu, Marcus Skribek, Ulrika Harmenberg, Marco Gerling

Main menu

Table of contents

March 2023 - Volume 11 - 3

Basic tumor immunology

Clinical/translational cancer immunotherapy

Commentary

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

March 2023 - Volume 11 - 3

Basic tumor immunology

Clinical/translational cancer immunotherapy

Commentary

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction